Lifevantage (LFVN) Competitors

Lifevantage has a consensus target price of $5.00, suggesting a potential downside of 26.04%. Given Lifevantage's stronger consensus rating and higher possible upside, analysts plainly believe Lifevantage is more favorable than Yatsen.

35.3% of Lifevantage shares are held by institutional investors. 29.0% of Yatsen shares are held by insiders. Comparatively, 22.0% of Lifevantage shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Yatsen has a beta of -1.55, suggesting that its stock price is 255% less volatile than the broader market. Comparatively, Lifevantage has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

Lifevantage has a net margin of 2.94% compared to Yatsen's net margin of -3.04%. Lifevantage's return on equity of 23.89% beat Yatsen's return on equity.

In the previous week, Lifevantage had 3 more articles in the media than Yatsen. MarketBeat recorded 3 mentions for Lifevantage and 0 mentions for Yatsen. Lifevantage's average media sentiment score of 0.64 beat Yatsen's score of 0.00 indicating that Lifevantage is being referred to more favorably in the news media.

Lifevantage has lower revenue, but higher earnings than Yatsen. Yatsen is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Lifevantage currently has a consensus target price of $5.00, indicating a potential downside of 26.04%. Niagen Bioscience has a consensus target price of $10.33, indicating a potential upside of 231.20%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Niagen Bioscience is more favorable than Lifevantage.

Lifevantage has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market.

In the previous week, Niagen Bioscience had 22 more articles in the media than Lifevantage. MarketBeat recorded 25 mentions for Niagen Bioscience and 3 mentions for Lifevantage. Lifevantage's average media sentiment score of 0.64 beat Niagen Bioscience's score of -0.01 indicating that Lifevantage is being referred to more favorably in the media.

Niagen Bioscience has a net margin of 12.39% compared to Lifevantage's net margin of 2.94%. Lifevantage's return on equity of 23.89% beat Niagen Bioscience's return on equity.

Niagen Bioscience has lower revenue, but higher earnings than Lifevantage. Lifevantage is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lifevantage has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Nu Skin Enterprises has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 82.8% of Nu Skin Enterprises shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by insiders. Comparatively, 2.8% of Nu Skin Enterprises shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Nu Skin Enterprises has higher revenue and earnings than Lifevantage. Nu Skin Enterprises is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

In the previous week, Lifevantage had 1 more articles in the media than Nu Skin Enterprises. MarketBeat recorded 3 mentions for Lifevantage and 2 mentions for Nu Skin Enterprises. Nu Skin Enterprises' average media sentiment score of 0.88 beat Lifevantage's score of 0.64 indicating that Nu Skin Enterprises is being referred to more favorably in the news media.

Lifevantage pays an annual dividend of $0.20 per share and has a dividend yield of 3.0%. Nu Skin Enterprises pays an annual dividend of $0.24 per share and has a dividend yield of 4.4%. Lifevantage pays out 44.4% of its earnings in the form of a dividend. Nu Skin Enterprises pays out 21.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Lifevantage has raised its dividend for 3 consecutive years. Nu Skin Enterprises is clearly the better dividend stock, given its higher yield and lower payout ratio.

Lifevantage currently has a consensus target price of $5.00, indicating a potential downside of 26.04%. Given Lifevantage's stronger consensus rating and higher possible upside, research analysts plainly believe Lifevantage is more favorable than Nu Skin Enterprises.

Nu Skin Enterprises has a net margin of 3.78% compared to Lifevantage's net margin of 2.94%. Lifevantage's return on equity of 23.89% beat Nu Skin Enterprises' return on equity.

In the previous week, Lifevantage had 2 more articles in the media than Waldencast. MarketBeat recorded 3 mentions for Lifevantage and 1 mentions for Waldencast. Lifevantage's average media sentiment score of 0.64 beat Waldencast's score of 0.00 indicating that Lifevantage is being referred to more favorably in the news media.

Waldencast currently has a consensus price target of $2.33, suggesting a potential upside of 67.87%. Lifevantage has a consensus price target of $5.00, suggesting a potential downside of 26.04%. Given Waldencast's stronger consensus rating and higher possible upside, equities analysts clearly believe Waldencast is more favorable than Lifevantage.

Lifevantage has a net margin of 2.94% compared to Waldencast's net margin of 0.00%. Lifevantage's return on equity of 23.89% beat Waldencast's return on equity.

42.0% of Waldencast shares are held by institutional investors. Comparatively, 35.3% of Lifevantage shares are held by institutional investors. 22.0% of Lifevantage shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Lifevantage has lower revenue, but higher earnings than Waldencast.

Waldencast has a beta of -0.13, indicating that its stock price is 113% less volatile than the broader market. Comparatively, Lifevantage has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.